by Truveta Research | Aug 22, 2024 | Research, Research Insights
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker, DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
by Truveta Research | Jul 23, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2024 increased slightly relative to March 2024 (+8.43%). Month-over-month anti-diabetic medication (ADM) prescribing increased in April and May 2024 then decreased slightly in June...
by Truveta Research | Jul 8, 2024 | Research
Truveta Research’s comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine. Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications,...
by Truveta staff | May 28, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased throughout the first quarter of 2024 (+20.9% increase in March 2024 compared to December 2023). First-time prescribing rates (first-time GLP-1 RA prescriptions per total...
by Truveta staff | May 14, 2024 | News
Truveta Research and collaborators Anupam B. Jena, MD, PhD and Christopher Worsham, MD, MPH received the ISPOR 2024 Best General Poster Research Presentation Award for their poster presentation, HSD72: Baseline A1C and BMI Trends for People with Type 2 Diabetes...